Ayahuasca: The Neuroscience of the Vine

Somewhere in the Amazon basin, centuries before anyone could spell “monoamine oxidase,” people solved a pharmacological problem that should have been impossible to solve by trial and error. The visionary molecule they were after — DMT, found in the leaves of the chacruna shrub — is destroyed the instant it hits the human gut, broken down by an enzyme before it can ever reach the brain. Swallow it and nothing happens. But combine those leaves with a particular jungle vine, and the molecule survives, crosses into the brain, and opens a six-hour visionary state. Out of tens of thousands of Amazonian plant species, the tradition found the two that, and only that, work together. This is the neuroscience of ayahuasca: the chemistry of that synergy, what the brew does to the brain, what the clinic is now finding, and why the same mechanism that makes it work also makes it dangerous.

The Synergy: Why It Takes Two Plants

Ayahuasca is a brew of two plants, and the genius is in the combination. The first, Psychotria viridis (chacruna), supplies the active molecule: N,N-dimethyltryptamine (DMT), the same compound found across the natural world and in trace amounts in the human body. DMT is a powerful psychedelic — but only if it reaches the brain. Taken by mouth on its own, it never does: an enzyme called monoamine oxidase (MAO), abundant in the gut wall and liver, dismantles DMT before it can be absorbed. Orally, pure DMT is inert.

The second plant solves exactly that problem. Banisteriopsis caapi — the vine that gives ayahuasca its name — contains a family of compounds called β-carbolines: harmine, harmaline, and tetrahydroharmine (THH). These are monoamine oxidase inhibitors (MAOIs). By temporarily blocking MAO, the vine shields the DMT from destruction long enough for it to enter the bloodstream and cross into the brain. Neither plant produces the ayahuasca experience alone — the leaf has the vision but can’t deliver it; the vine has the key but no door. Together, they are one of the most sophisticated pieces of plant pharmacology humans have ever used. How a preliterate tradition discovered this specific pairing among the rainforest’s staggering botanical diversity remains one of ethnobotany’s genuine mysteries.

Inside the Brew: DMT, Harmine, and THH

Pharmacologically, ayahuasca is doing several things at once. The DMT is the visionary engine: like psilocybin and LSD, it is an agonist at the serotonin 2A (5-HT2A) receptor on cortical neurons, the receptor responsible for the classic psychedelic state. The β-carbolines are not merely passive protectors. Harmine, usually the most abundant, is a reversible, selective inhibitor of MAO-A — reversible being important, because it means the effect wears off cleanly rather than lingering for weeks like the old pharmaceutical MAOIs. Tetrahydroharmine (THH) adds another layer: it weakly inhibits MAO and also blocks the serotonin transporter (SERT), nudging the system in an SSRI-like direction. The result is a serotonergic state that is broader and longer than DMT alone — the smoked molecule lasts minutes; the brew lasts four to six hours, with a slow rise, a plateau, and a gradual return. The tradition didn’t just make DMT oral; it made it a journey.

The Brain on Ayahuasca: Quieting the Self

When researchers first put ayahuasca in a scanner, they found the now-familiar signature of the psychedelic state. In a landmark study, Palhano-Fontes and colleagues (PLOS One, 2015) imaged volunteers before and about forty minutes after drinking, and saw a clear reduction in the activity and connectivity of the default mode network (DMN) — the midline system, anchored by the posterior cingulate and medial prefrontal cortices, that maintains the ongoing sense of a narrative self. As DMN dominance fell, subjects reported the characteristic loosening of self-boundaries, the feeling of unity, the ego dissolution that recurs across all the classic psychedelics. Ayahuasca reaches the same destination as psilocybin — the quieting of the self-network — but by a different route and on a different clock: oral, gradual, and long. Later work extended the picture, showing changes in the salience and default mode networks that persisted into the days after a session, hinting at why a single experience can leave a lasting mark.

The Clinic: A Rapid Antidepressant

The most important modern finding came from Brazil. Palhano-Fontes, Araújo and colleagues (Psychological Medicine, 2019) ran what was, remarkably, the first randomized, placebo-controlled trial of any psychedelic in treatment-resistant depression — 29 patients who had failed at least two prior antidepressants, given a single dose of ayahuasca or a carefully matched placebo (a bitter brown liquid designed to mimic the taste and produce mild effects). The result: ayahuasca produced significantly greater improvement than placebo, and it did so rapidly — response rates were markedly higher in the ayahuasca group by the end of the first week, a speed conventional antidepressants cannot match. A companion analysis found that a single dose modulated serum BDNF, the brain’s key plasticity signal, with changes that tracked the antidepressant response. Small as it was, the trial put a centuries-old jungle brew on the same evidential map as the most advanced psychiatric research.

More Than a Delivery System: The β-Carbolines Themselves

It would be a mistake to treat the vine as nothing but a chemical chaperone for the DMT. The β-carbolines appear to be therapeutic in their own right. Laboratory work — notably by Morales-García and colleagues — has shown that harmine and related compounds stimulate the proliferation of neural stem cells and promote neurogenesis, the birth of new neurons, alongside anti-inflammatory effects. Several of ayahuasca’s constituents converge on pathways implicated in depression: serotonergic signaling, neuroplasticity, BDNF, and neuroinflammation. This is part of why ayahuasca is so interesting to neuroscience — it is not a single drug but a combination therapy assembled by tradition, in which the molecule that opens the mind and the molecules that protect and repair the brain arrive in the same cup.

La Purga: The Purge

No honest account of ayahuasca omits the vomiting. “La purga” — the purge — is so central that in many traditions it is considered not a side effect but the point: a physical, emotional, and symbolic cleansing. Physiologically, it has real drivers: the brew is a potent serotonergic agent, and the gut is dense with serotonin receptors (the 5-HT3 receptor in particular triggers nausea), so vomiting and diarrhea are pharmacologically predictable. Crying, yawning, trembling, and sweating often accompany it. In the ceremonial frame, the purge is read as the release of what the body and psyche have been holding — and many participants describe a profound sense of relief and lightness afterward. The neuroscience and the tradition agree on the timing, if not the language: the brew moves something out.

Decades of Use: What the Long-Term Brain Shows

Because ayahuasca has been used ceremonially for generations — and legally, in syncretic churches like Santo Daime and the União do Vegetal — researchers can study people who have drunk it hundreds of times. The findings are reassuring and intriguing. Bouso and colleagues found structural differences in the cortex of long-term users — a thinning of the posterior cingulate cortex (a core DMN hub) that correlated with the intensity and duration of use, alongside thickening in the anterior cingulate. Crucially, these long-term users showed no evidence of cognitive impairment or psychiatric harm; if anything, measures of wellbeing, and in some studies personality and resilience, trended favorably. Decades of regular use, in a structured ceremonial context, have not produced the deterioration one might fear — a finding that continues to surprise researchers and that sharply distinguishes a held tradition from casual consumption.

Risks and the MAOI Problem

The very mechanism that makes ayahuasca work is also its principal danger. Because the β-carbolines inhibit monoamine oxidase, ayahuasca behaves like an MAOI drug — and MAOIs have serious interactions. Combining ayahuasca with SSRIs, SNRIs, or other serotonergic medications can trigger serotonin syndrome, a potentially fatal surge of serotonin; people on antidepressants must taper off under medical supervision well in advance, which is itself risky. Certain foods high in tyramine and a range of other drugs are also contraindicated, as are personal or family histories of psychosis or bipolar I, and significant cardiac conditions. The brew is physically demanding — it raises heart rate and blood pressure — and tragedies have occurred at unregulated “retreats” lacking screening or medical support. Reversible MAO inhibition makes the margin safer than the old irreversible drugs, but ayahuasca is not a substance to approach casually, self-administer, or combine with medication. This article is education, not medical advice.

What the Evidence Cannot Yet Tell Us

Ayahuasca is simultaneously one of the oldest and one of the youngest subjects in psychedelic science. The flagship depression trial was small; larger, multi-site studies are only now underway. The brew itself is variable — concentrations of DMT and β-carbolines differ between batches and traditions — which complicates dosing and replication. And ayahuasca is almost never taken outside a rich context of music, ceremony, diet, and community, making it genuinely hard to separate the molecule’s effects from the container’s. That entanglement is part of what the tradition would call the medicine, and part of what makes it scientifically thorny. The honest posture is the field’s usual one: real promise, held with rigor and respect.

The Synthesis

Ayahuasca is a piece of pharmacological genius that no laboratory designed. It takes a molecule the body refuses to absorb and, by pairing it with the right plant, turns it into a hours-long encounter with the dissolved self — quieting the same brain network that meditation trains and psilocybin releases, while delivering compounds that may help the brain repair itself. The clinic is beginning to confirm what the Amazon has claimed for centuries, and the long-term data suggest the tradition’s container has kept it remarkably safe. The cup holds two plants, a solved enzyme, a quieted self, and a science still catching up to a knowledge older than writing.